Literature DB >> 22056890

Successful long-term treatment with pemetrexed of NSCLC associated with EML4-ALK and low thymidylate synthase expression.

Masayuki Takeda1, Isamu Okamoto, Kazuko Sakai, Kaoru Tanaka, Masaaki Terashima, Kazuto Nishio, Kazuhiko Nakagawa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22056890     DOI： 10.1016/j.cllc.2011.09.003

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN： 1525-7304            Impact factor:   4.785


× No keyword cloud information.
  4 in total

Review 1.  ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it.

Authors:  Christian Rolfo; Francesco Passiglia; Marta Castiglia; Luis E Raez; Paul Germonpre; Ignacio Gil-Bazo; Karen Zwaenepoel; Annemieke De Wilde; Giuseppe Bronte; Antonio Russo; Jan P Van Meerbeeck; Paul Van Schil; Patrick Pauwels
Journal:  Transl Lung Cancer Res       Date:  2014-08

2.  Biomarkers that currently affect clinical practice: EGFR, ALK, MET, KRAS.

Authors:  M D Vincent; M S Kuruvilla; N B Leighl; S Kamel-Reid
Journal:  Curr Oncol       Date:  2012-06       Impact factor: 3.677

Review 3.  ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC.

Authors:  Francesca Casaluce; Assunta Sgambato; Paolo Maione; Antonio Rossi; Carmine Ferrara; Alba Napolitano; Giovanni Palazzolo; Fortunato Ciardiello; Cesare Gridelli
Journal:  Target Oncol       Date:  2013-01-17       Impact factor: 4.493

Review 4.  Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice.

Authors:  Antonio Passaro; Chiara Lazzari; Niki Karachaliou; Gianluca Spitaleri; Alessia Pochesci; Chiara Catania; Rafael Rosell; Filippo de Marinis
Journal:  Onco Targets Ther       Date:  2016-10-17       Impact factor: 4.147
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.